POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (latest WHO data):   India 18,327    Brazil 75,102    Russia 11,024    The United Kingdom 6,573    France 24,739    Spain 2,676    Italy 22,845    Turkey 11,322    Germany 10,580    Columbia 3,565    Argentina 11,767    Mexico 7,521    Poland 15,831    Iran 8,367    South Africa 1,404    Ukraine 10,155    Indonesia 6,971    Peru 4,878    Czechia 14,714    The Netherlands 4,161    Canada 2,832    Chile 5,331    Romania 4,271    Iraq 5,127    Sweden 4,864    Philippines 3,037    Pakistan 1,579    Serbia 3,866    Austria 2,691    Hungary 6,369    Japan 1,164    Jordan 4,584    United Arab Emirates 3,072    Lebanon 3,202    Slovakia 2,423    Malaysia 2,154    Belarus 1,174    Ecuador 1,335    Bulgaria 2,198    Palestine 1,826    Greece 2,217    Kuwait 1,613    Slovenia 1,019    Moldova 1,800    Paraguay 1,439    Estonia 1,534    China 21    Singapore 9    New Zealand 9    Australia 18    South Korea 417   

U.S. begins final tests of coronavirus vaccine candidate

Christian Fernsby |
Phase three trials began on Monday of a candidate vaccine against the novel coronavirus in the U.S., with an expected enrollment of 30,000 volunteers, the National Institutes of Health announced.

Article continues below



Topics: U.S.   

The vaccine was codeveloped by biotechnology company Moderna, Inc., based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID).

The trial will be conducted at 89 U.S. clinical research sites with adult volunteers who do not have coronavirus, according to the statement.

NIAID Director Anthony Fauci said results from earlier clinical testing indicated that the vaccine was "safe and immunogenic, supporting the initiation of a Phase 3 clinical trial."

"This scientifically rigorous, randomized, placebocontrolled trial is designed to determine if the vaccine can prevent COVID-19 and for how long such protection may last."

The vaccine efficacy trial is the first to be implemented under Operation Warp Speed, a governmental program that aims to begin delivering millions of doses of an effective virus vaccine by the end of 2020.

The trial is designed to determine if the vaccine can prevent symptomatic COVID-19 after two doses and it aims to study whether the vaccine can prevent severe infection with or without disease symptoms, the NIH said.

It also seeks to answer whether the vaccine can prevent death caused by the virus and if just one dose can prevent symptomatic COVID-19, among other objectives.

Trial volunteers will receive two injections approximately 28 days apart and some participants will be assigned at random to a control group that will be administered placebo doses.


What to read next

3-in-1 vaccine against traveler's diarrhea
Candidate Ebola vaccine still effective when highly diluted
Zika vaccine works in early human trial